Results 171 to 180 of about 69,627 (255)

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal, Frédéric Baroz, Philippe Boileau, Michael A. Tsoukas, Abhinav Sharma, Thomas A. Mavrakanas   +5 more
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

The utilization of c-type natriuretic peptide levels on experimental muscle and kidney ischemia/reperfusion model. [PDF]

Malawi Med J
Çakırköse Ö, Kesici U, Kesici S, Sipahi M, Tokgöz VY, Güvendi GF, Avcı E, Şen TM, Kara H, Tosun A, Küçükarslan MN.   +10 more
europepmc   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li, Benjamin Yarnoff, Claudia H. T. Tam, Juliana C. N. Chan, Ronald C. W. Ma, Juliana N. M. Lui, Hong Kong Diabetes Biobank Study Group   +6 more
wiley   +1 more source

Auto/Paracrine C-Type Natriuretic Peptide/Cyclic GMP Signaling Prevents Endothelial Dysfunction. [PDF]

Int J Mol Sci
Werner F, Naruke T, Sülzenbrück L, Schäfer S, Rösch M, Völker K, Krebes L, Abeßer M, Möllmann D, Baba HA, Schweda F, Zernecke A, Kuhn M.   +12 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Efficiency of C-type natriuretic peptide on improvement of Iraqi local ram's epididymal sperms. [PDF]

Open Vet J
Khadim MS, Zaid NW.
europepmc   +1 more source

C-type Natriuretic Peptide-induced PKA Activation Promotes Endochondral Bone Formation in Hypertrophic Chondrocytes.

Endocrinology, 2022
Hirota K, Hirashima T, Horikawa K, Yasoda A, Matsuda M.   +4 more
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. [PDF]

Sci Transl Med
Lu Z, Verginadis I, Kumazoe M, Castillo GM, Yao Y, Guerra RE, Bicher S, You M, McClung G, Qiu R, Xiao Z, Miao Z, George SS, Beiting DP, Nojiri T, Tanaka Y, Fujimura Y, Onda H, Hatakeyama Y, Nishimoto-Ashfield A, Bykova K, Guo W, Fan Y, Buynov NM, Diehl JA, Stanger BZ, Tachibana H, Gade TP, Puré E, Koumenis C, Bolotin EM, Fuchs SY.   +31 more
europepmc   +1 more source